# Endevica Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endevica-bio

- Industry: Biotechnology
- Headquarters: Northbrook, US
- Website: www.endevicabio.com
- Total disclosed funding: $1.7M
- Latest round: Series A (Jun 1, 2016)
- Investors on record: 1

## About

Based in Illinois, US, and founded by Kenneth Gruber in 2009, Endevica Bio operates as a biotechnology company engaged in the development of drugs to treat cachexia due to cancer. In January 2023, the firm raised USD 10 million in series B funding. The firm as of January 2023, is led by its CEO and Executive Chairman, Russell Potterfield.

The company is working on the development of a peptide therapeutic for treating cachexia due to cancer and other chronic conditions such as renal failure and congestive heart failure. The company’s product primary molecule TCMCB07 is a melanocortin-3/4 (MC4R) antagonist peptide that helps in significant lean muscle mass gain during the administration of the drug. TCMCB07, as of January 2023, has completed its pre-clinical animal trials.

The company plans to utilize its January 2023 funding to advance its research and development of TCMB07 for treatment of cachexia.

## Funding rounds

- Series A, Jun 1, 2016, $1.7M — Centennial Investors

## Investors

- Centennial Investors (https://capitalatlas.ai/funds/centennial-investors) — Series A